Tetrahydroharmine (THH) – Kodiac biolabs

Our opinion on this compoundNiche research probe

33/100

A structurally distinct SRI beta-carboline with narrow utility as an ayahuasca pharmacology probe

Look, THH is interesting in a specific and narrow way. It’s the third harmala alkaloid from Banisteriopsis caapi, and the fact that its primary mechanism is serotonin reuptake inhibition rather than MAO-A inhibition actually matters a lot if you’re trying to understand what ayahuasca is doing pharmacologically. Harmine and harmaline get most of the attention because MAO-A inhibition is the obvious DMT-potentiation story, but THH contributes a distinct serotonergic vector that doesn’t map cleanly onto that narrative. That’s genuinely worth knowing.

The problem is that the research value is almost entirely contextual. Outside of ayahuasca pharmacology work, theres very little reason to reach for THH. The SRI mechanism is well understood in general, and if you want to study serotonin reuptake inhibition you have cleaner, better-characterized tools. THH’s structure is unusual for an SRI, which gives it some probe value for mapping binding site geometry or studying beta-carboline scaffold activity, but that’s a niche question inside a niche question. The evidence base reflects this: most of the data on THH comes from multi-component ayahuasca studies where its individual contribution is impossible to isolate cleanly. Standalone in vitro characterization exists, but replicated in vivo work on THH specifically is sparse.

Translational signal is weak. Human pharmacology data is derived from ayahuasca ceremony contexts, with THH appearing in plasma alongside harmine, harmaline, and DMT. Disentangling its behavioral or physiological effects from that cocktail in actual humans hasn’t really been done at a level that would satisfy a serious reviewer. The growing clinical interest in ayahuasca for depression and trauma is exciting, but that work is focused on the preparation as a whole, not on THH as a manipulable variable.

We think the honest framing here is: if you’re running an ayahuasca pharmacology program and you want to attribute specific components of the brew’s effects to specific alkaloids, THH is a tool you need in the lab. That’s a legitimate research question and THH is genuinely necessary for answering it. Outside that specific program, it’s hard to build a case for prioritizing it. The novelty is low, the mechanism while structurally distinctive isn’t paradigm-shifting, and the clinical picture for the isolated compound is essentially blank. Solid reference standard, not a research priority on its own terms.

Novelty: 32
Mechanism promise: 38
In-category differentiation: 35
Evidence quality: 28
Translational signal: 22
Research bench value: 42

Rationale THH scores low on novelty and translational signal because its pharmacology has been characterized for decades and clinical data exists only in the context of whole ayahuasca, not isolated THH. Its value is real but tightly scoped: as a reference SRI beta-carboline for researchers dissecting the component pharmacology of the brew.

Beta-carboline (tetrahydro reduced)

A reduced tetrahydro-beta-carboline from Banisteriopsis caapi; a serotonin reuptake inhibitor and minor MAO-A inhibitor in ayahuasca.

Abstract

Tetrahydroharmine (THH, 7-methoxy-1-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole; CAS 17019-01-1; molecular formula C13H16N2O; molecular weight 216.28) is a tetrahydro-reduced beta-carboline alkaloid from Banisteriopsis caapi, the third major harmala alkaloid alongside harmine and harmaline. Distinct from the parent oxidized beta-carbolines by a different mechanism: THH is a moderate serotonin reuptake inhibitor (SRI) rather than an MAO-A inhibitor; the MAO-A activity is minor compared to harmine/harmaline. The SRI activity contributes a distinct serotonergic component to ayahuasca pharmacology beyond the MAO-mediated DMT potentiation. Plasma half-life is comparable to other beta-carbolines (approximately 2 to 3 hours). Used as a reference SRI beta-carboline in ayahuasca pharmacology research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-339Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.